tiprankstipranks
Advertisement
Advertisement
Analyst Reiterates Buy on Janux Therapeutics, Citing Deep Pipeline Catalysts and Compelling Risk/Reward at Near-Zero Enterprise Value
PremiumRatingsAnalyst Reiterates Buy on Janux Therapeutics, Citing Deep Pipeline Catalysts and Compelling Risk/Reward at Near-Zero Enterprise Value
1M ago
Analyst Reiterates Buy on Janux, Citing Pipeline Upside and Key 2027 Catalyst; Price Target Maintained at $14
Premium
Ratings
Analyst Reiterates Buy on Janux, Citing Pipeline Upside and Key 2027 Catalyst; Price Target Maintained at $14
1M ago
Janux Therapeutics: Strong Balance Sheet and Advancing PSMA Pipeline Underpin Buy Rating and Favorable Risk-Reward
Premium
Ratings
Janux Therapeutics: Strong Balance Sheet and Advancing PSMA Pipeline Underpin Buy Rating and Favorable Risk-Reward
1M ago
Janux Therapeutics announces discontinuation of JANX008 clinical development
PremiumThe FlyJanux Therapeutics announces discontinuation of JANX008 clinical development
2M ago
Janux’s JANX011 First‑in‑Human Study: Early Safety Readout Could Shape Autoimmune Upside
Premium
Company Announcements
Janux’s JANX011 First‑in‑Human Study: Early Safety Readout Could Shape Autoimmune Upside
2M ago
Advancing PSMA Franchise and Validating TRACTr Platform Underpin Buy Rating on Janux Therapeutics
Premium
Ratings
Advancing PSMA Franchise and Validating TRACTr Platform Underpin Buy Rating on Janux Therapeutics
2M ago
Janux Therapeutics price target lowered to $23 from $25 at Evercore ISI
PremiumThe FlyJanux Therapeutics price target lowered to $23 from $25 at Evercore ISI
2M ago
Janux announces development candidate nomination under Bristol Myers collab
Premium
The Fly
Janux announces development candidate nomination under Bristol Myers collab
2M ago
Janux Therapeutics price target lowered to $80 from $100 at Truist
Premium
The Fly
Janux Therapeutics price target lowered to $80 from $100 at Truist
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100